Literature DB >> 18491062

Proline-rich sequence recognition domains (PRD): ligands, function and inhibition.

C Freund1, H-G Schmalz, J Sticht, R Kühne.   

Abstract

Low-affinity protein-protein interactions (PPI) between domains of modular proteins and short, solvent-exposed peptide sequences within their binding partners play an essential role in intracellular signaling. An important class of PPIs comprises proline-rich motifs (PRM) that are specifically recognized by PRM-binding domains (PRD). Aromatic side chains of the PRDs define the binding pockets that often recognize individual proline residues, while flanking sequences mediate specificity. Several of these PRM:PRD interactions are associated with cellular malfunction, cancer or infectious diseases. Thus, the design of PRM:PRD inhibitors by using structure-based molecular modeling as well as peptidomimetic approaches and high-throughput screening strategies is of great pharmacological interest. In this chapter we describe the molecular basis of PRM:PRD interactions, highlight their functional role in certain cellular processes and give an overview of recent strategies of inhibitor design.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18491062     DOI: 10.1007/978-3-540-72843-6_17

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  9 in total

1.  Dcp1 links coactivators of mRNA decapping to Dcp2 by proline recognition.

Authors:  Mark S Borja; Kirill Piotukh; Christian Freund; John D Gross
Journal:  RNA       Date:  2010-12-10       Impact factor: 4.942

2.  Targeting NOX2 via p47/phox-p22/phox Inhibition with Novel Triproline Mimetics.

Authors:  Jean-Baptiste Garsi; Balázs Komjáti; Gregorio Cullia; Imre Fejes; Melinda Sipos; Zoltán Sipos; Eszter Fördős; Piroska Markacz; Barbara Balázs; Nathalie Lancelot; Sylvie Berger; Eric Raimbaud; David Brown; Laurent-Michel Vuillard; Laure Haberkorn; Cyprian Cukier; Zoltán Szlávik; Stephen Hanessian
Journal:  ACS Med Chem Lett       Date:  2022-05-10       Impact factor: 4.632

3.  Distribution of the SynDIG4/proline-rich transmembrane protein 1 in rat brain.

Authors:  Lyndsey M Kirk; Shu W Ti; Hannah I Bishop; Mayra Orozco-Llamas; Michelle Pham; James S Trimmer; Elva Díaz
Journal:  J Comp Neurol       Date:  2015-12-29       Impact factor: 3.215

4.  High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.

Authors:  Larizbeth A Romero; Takamitsu Hattori; Mohamed A E Ali; Gayatri Ketavarapu; Akiko Koide; Christopher Y Park; Shohei Koide
Journal:  J Mol Biol       Date:  2021-12-24       Impact factor: 5.469

5.  Mutually Dependent Clustering of SynDIG4/PRRT1 and AMPA Receptor Subunits GluA1 and GluA2 in Heterologous Cells and Primary Neurons.

Authors:  Kristopher E Plambeck; Chun-Wei He; Hector H Navarro; Elva Díaz
Journal:  Front Mol Neurosci       Date:  2022-04-08       Impact factor: 6.261

6.  The bactofilin cytoskeleton protein BacM of Myxococcus xanthus forms an extended β-sheet structure likely mediated by hydrophobic interactions.

Authors:  David M Zuckerman; Lauren E Boucher; Kefang Xie; Harald Engelhardt; Jürgen Bosch; Egbert Hoiczyk
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

7.  Nitric Oxide Responsive Heavy Metal-Associated Gene AtHMAD1 Contributes to Development and Disease Resistance in Arabidopsis thaliana.

Authors:  Q Muhammad Imran; Noreen Falak; Adil Hussain; Bong-Gyu Mun; Arti Sharma; Sang-Uk Lee; Kyung-Min Kim; Byung-Wook Yun
Journal:  Front Plant Sci       Date:  2016-11-21       Impact factor: 5.753

8.  Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain.

Authors:  André Mischo; Oliver Ohlenschläger; Peter Hortschansky; Ramadurai Ramachandran; Matthias Görlach
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

9.  Putative bioactive motif of tritrpticin revealed by an antibody with biological receptor-like properties.

Authors:  Raghava Sharma; Suvendu Lomash; Dinakar M Salunke
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.